trifluorothymine deoxyriboside en es it fr

trifluorothymine deoxyriboside Brand names, trifluorothymine deoxyriboside Analogs

trifluorothymine deoxyriboside Brand Names Mixture

  • No information avaliable

trifluorothymine deoxyriboside Chemical_Formula

C41H42N4O8

trifluorothymine deoxyriboside RX_link

http://www.rxlist.com/cgi/generic2/verteporfin.htm

trifluorothymine deoxyriboside fda sheet

trifluorothymine_deoxyriboside FDA

trifluorothymine deoxyriboside msds (material safety sheet)

trifluorothymine deoxyriboside Synthesis Reference

No information avaliable

trifluorothymine deoxyriboside Molecular Weight

718.794 g/mol

trifluorothymine deoxyriboside Melting Point

No information avaliable

trifluorothymine deoxyriboside H2O Solubility

No information avaliable

trifluorothymine deoxyriboside State

Solid

trifluorothymine deoxyriboside LogP

3.743

trifluorothymine deoxyriboside Dosage Forms

Powder for solution to be mixed for injection (2mg verteporfin/mL reconstituted verteporfin)

trifluorothymine deoxyriboside Indication

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

trifluorothymine deoxyriboside Pharmacology

Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

trifluorothymine deoxyriboside Absorption

No information avaliable

trifluorothymine deoxyriboside side effects and Toxicity

Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.

trifluorothymine deoxyriboside Patient Information

trifluorothymine deoxyriboside Organisms Affected

Humans and other mammals